The FDA has issued an Emergency Use Authorization (EUA) to permit the use of the unapproved product, REGEN-COV (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 in adult patients and pediatric patients 12 years and older weighing at least 40 kg (88 lbs.) who are at high risk for progression to severe COVID-19, including hospitalization or death. These patients must fit one of the following:
- Have received a positive COVID-19 PCR or antigen and experiencing mild to moderate COVID-19 symptoms for <10 days
- Are not fully vaccinated and have had close contact exposure to an individual infected with SARS-CoV-2
Monoclonal antibody treatments are currently only available at our Millard location.
Schedule Your Treatment Appointment
MILLARD
12741 Q St
Omaha, NE 68137-3211
Treatment Available:
REGEN-COV® (casirivimab 600 mg/ imdevimab 600 mg) subcutaneous injection
Physicians: Download our Physician Referral Fax Form (PDF)
Some answers to common questions are below.
Frequently Asked Questions
Fact Sheets for Recipients/Caregivers
- Pfizer (12+) Fact Sheet for Recipients/Caregivers – updated 11-19-2021
- Pfizer (5-11) Fact Sheet for Recipients/Caregivers – updated 10-29-2021
- Moderna Fact Sheet for Recipients/Caregivers – updated 11-19-2021
- Janssen Fact Sheet for Recipients/Caregivers – updated 11-19-2021
- REGEN-COV Fact Sheet for Recipients/Caregivers – updated 11-2021
Fact Sheet for Healthcare Providers
- Pfizer (12+) Fact Sheet for Healthcare Providers – updated 11-19-2021
- Pfizer (5-11) Fact Sheet for Healthcare Providers – updated 10-29-2021
- Moderna Fact Sheet for Healthcare Providers – updated 11-19-2021
- Janssen Fact Sheet for Healthcare Providers – updated 11-19-2021
- REGEN-COV Fact Sheet for Healthcare Providers – Updated 11-2021
